Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Gv Prasad

    Jump to

    • Dr. Reddy’s to invest Rs 700 cr in biosimilars and API: GV Prasad on investments & AI

      Dr. Reddy’s plans to invest Rs 700 crore into capacity expansion of biosimilars and Active Pharmaceutical Ingredients. GV Prasad, Co-chairman and Managing Director of Dr. Reddy Laboratories shares his insights on future investments and artificial intelligence. We have seen how AI has reduced the amount of experimentation we need to do, bring more precision to our work, and give us ideas that normal human beings wouldn’t have thought about, he said while explaining how they are using machine learning to understand scaleups. For information watch this interview.

    • Dr Reddy's Q2 profit sinks 60%, US & EMs biz drag revenue 10%

    • New launches to drive growth in second quarter: Dr Reddy's

    • Will resolve issues raised by USFDA in a timely manner: DRL

    • Dr Reddy's gets FDA warning letter for three drug plants

    • Plan to revamp systems as per FDA expectations: Dr Reddy's

    • Dr Reddy's Q1 net up 14% at Rs 626 cr led by US & India biz

    • See growth over base of last year: Dr Reddy's CEO

    • Dr Reddy's up 2% on pact with Hetero for Hepatitis drug

    • Core generics, API biz to drive FY16 growth: Dr Reddy's

    • Likely to file 2 NDAs worth $100 m each soon: Dr Reddy's

    • BioAsia 2014: A holistic approach to product innovation

    • Delay in clinical trials approval affecting pharma sector

    • GV Prasad: You cannot have a company driven by one person

      Dr Reddy‘s Laboratories' GV Prasad says that an organisation must be able to sustain changing ownership, technologies, products and strategies

    • Dr Reddy's Lab appoints GV Prasad as chairman

      Pharma company Dr Reddy's Laboratories Ltd Monday said it has appointed GV Prasad as chairman and CEO, and Satish Reddy as cice chairman.

    • Dr Reddy's Labs to acquire OctoPlus NV for euro 27.4m

      Drug maker Dr Reddy's Laboratories today said it has decided to acquire Netherlands-based OctoPlus NV, a speciality pharmaceutical company, for about 27.4 million euros (about Rs 193 crore).

    • Growth rates may decline in next few years: Dr Reddy's

      Country's second largest drug maker Dr Reddy's Laboratories today said its growth rates are likely to decline in the next few years due to expiry of many of its patents.

    • Dr Reddy's gets USFDA ok for deep vein thrombosis injection

      Dr Reddy’s Laboratories has received final approval from the US Food and Drugs Administration (FDA) to sell Fondaparinux Sodium injection, which is used for the treatment and prevention of deep vein thrombosis (DVT).

    • Union Budget 2011: India Inc assesses the math

      In an interview with CNBC-TV18's Menaka Doshi, an illustrious panel of business leaders including Chanda Kochhar, MD and CEO, ICICI Bank, Harsh Mariwala, CMD, Marico, Baba Kalyani, CMD, Bharat Forge, GV Prasad, Dr Reddy's and YM Deosthalee, Whole-Time Director and CFO, L&T, assess the math of the budget.

    • Unsure of how biz will shape up in German mkt: Dr Reddy's

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347